Introduction

Gemtesa (vibegron) has moved beyond its original positioning as a newer treatment for overactive bladder (OAB). In the United States, the β3-adrenergic receptor agonist now has an expanded indication covering adults with OAB and men receiving pharmacological treatment for benign prostatic hyperplasia (BPH). The expansion, combined with newer clinical evidence from the COURAGE program, has strengthened the product’s position in a therapeutic market where physicians have historically relied on antimuscarinic medicines and another β3 agonist, mirabegron.

The commercial importance of Gemtesa is closely tied to the changing treatment preferences within OAB. Antimuscarinic therapies can cause adverse effects such as dry mouth and constipation, while concerns about anticholinergic burden and potential cognitive effects have made the tolerability profile of non-antimuscarinic options increasingly relevant, particularly for older populations. The 2024 American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline recognizes β3 agonists as an important pharmacological option and notes differences in side-effect profiles between β3 agonists and antimuscarinic medicines.

For Sumitomo Pharma, Gemtesa has also become an important commercial asset. The company reported U.S. Gemtesa sales of $431 million for fiscal 2024 and has identified the product as one of its major U.S. growth products. In 2025, the company raised its fiscal-year sales forecast for Gemtesa to $588 million after stronger-than-expected first-half performance.

From a healthcare market perspective, Gemtesa is therefore relevant for more than its pharmacological profile. Its trajectory illustrates how an established prescription therapy can expand its commercial opportunity through label differentiation, evidence generation in specific patient populations, and targeted positioning against competing mechanisms.

What Is Gemtesa?

Gemtesa is the U.S. brand name for vibegron, an orally administered selective β3-adrenergic receptor agonist. The U.S. Food and Drug Administration approved Gemtesa on December 23, 2020, initially for adults with OAB characterized by urge urinary incontinence, urgency, and urinary frequency.

The drug works by activating β3-adrenergic receptors in the detrusor muscle of the urinary bladder. Activation promotes relaxation of the bladder during the storage phase, allowing the bladder to accommodate urine while reducing involuntary contractions associated with urgency and urge urinary incontinence. The European Medicines Agency describes the same fundamental mechanism for vibegron under the brand Obgemsa.

Gemtesa is supplied as a 75 mg tablet and is taken once daily, with or without food. The U.S. label also allows the tablet to be crushed and mixed with applesauce, a formulation characteristic that can be relevant when swallowing tablets is difficult.

From OAB treatment to a broader male population

The most important regulatory development in the United States came in late 2024, when the Gemtesa label was expanded to include OAB symptoms in adult men receiving pharmacological therapy for BPH. The approved population therefore includes men whose lower urinary tract symptoms persist despite pharmacological management of their underlying prostate condition.

This distinction matters commercially. BPH is a large and established urology treatment category, and OAB symptoms can coexist with BPH. A therapy that can be incorporated into pharmacological management of these patients provides an opportunity to reach urology practices and patient groups that overlap with existing BPH treatment pathways.

The expansion was supported by the phase 3 COURAGE program, which evaluated vibegron in men aged 45 years and older with OAB symptoms while receiving α-blocker therapy, with or without a 5α-reductase inhibitor, for BPH.

Recent Developments and Trends

COURAGE strengthens the evidence base in men with BPH

The COURAGE phase 3 trial has become an important part of Gemtesa’s post-approval evidence strategy. The randomized study included 1,105 men with OAB and BPH who were already receiving pharmacological treatment for BPH. At week 12, vibegron produced statistically significant improvements compared with placebo in daily micturitions and urgency episodes, as well as measures of nocturia, urge urinary incontinence, storage symptoms, and voided volume.

A subsequent responder analysis published in 2025 examined whether the improvements translated into clinically meaningful outcomes. Among 1,080 participants included in the analysis, greater proportions of men receiving vibegron achieved predefined response thresholds for micturition frequency, nocturia, and urge urinary incontinence compared with placebo. Improvements were generally maintained through week 24.

The clinical evidence was extended further through longer-term analyses. A 2026 publication examining bladder function and safety reported that differences in postvoid residual urine volume and maximum urinary flow rate between vibegron and placebo were minimal during the 24-week trial. Urinary retention occurred in 0.9% of participants receiving vibegron and 0.7% receiving placebo. The investigators did not identify a treatment-related bladder-function safety signal in the studied population.

These findings are particularly relevant because urinary retention is an important clinical consideration when treating men with BPH and bladder outlet obstruction.

Long-term evidence supports continued use

Gemtesa’s evidence base is not limited to short-duration trials. The EMPOWUR extension study followed patients for an additional 40 weeks after the initial 12-week trial. Among 505 participants who received at least one dose during the extension, 430 completed the study. The most commonly reported adverse events included hypertension, urinary tract infection, headache, nasopharyngitis, and dry mouth.

The FDA labeling similarly incorporates longer-term safety data from the extension program. In the original OAB extension, 181 patients receiving Gemtesa were treated for a total of one year.

A 2025 comprehensive review of vibegron concluded that phase 3 studies support reductions in urgency, urinary frequency, and urgency urinary incontinence, while highlighting the drug’s tolerability profile compared with antimuscarinic therapy.

Positioning against antimuscarinic therapy

The OAB market is increasingly influenced by tolerability considerations. Antimuscarinic medicines remain established therapies, but dry mouth, constipation, blurred vision, and urinary retention can affect treatment persistence. The AUA/SUFU guideline notes that β3 agonists generally have lower rates of dry mouth and constipation than antimuscarinic medicines and may have less effect on postvoid residual volume.

Cognitive health is another area receiving attention. Observational research continues to examine the relationship between long-term anticholinergic exposure and dementia risk, particularly among older adults. Such evidence does not establish that every antimuscarinic causes cognitive decline, and observational findings require careful interpretation, but it has contributed to broader interest in non-anticholinergic OAB therapies.

For Gemtesa, this creates a market-positioning opportunity based on mechanism rather than simply price or incremental efficacy.

Commercial momentum under Sumitomo Pharma

Gemtesa is now managed within Sumitomo Pharma’s U.S. business. The company’s strategy has increasingly emphasized the product as a core commercial asset alongside ORGOVYX and MYFEMBREE.

Sumitomo Pharma reported Gemtesa U.S. sales of $431 million in fiscal 2024. Its original fiscal 2025 forecast was $572 million, and in October 2025 the company raised that forecast to $588 million after first-half sales reached $297 million, representing 109% of its original first-half plan. The company attributed the performance to stronger volume and changes in its pricing and reimbursement strategy.

The company has also identified Gemtesa and ORGOVYX as central to its 2026–2028 growth strategy. Its Boost 2028 plan targets combined sales of more than ¥350 billion for the two products in fiscal 2028.

Impact on the Healthcare Industry

Expanding treatment options for OAB

Gemtesa contributes another non-antimuscarinic option to a therapeutic area in which medication selection often depends on efficacy, tolerability, comorbidities, and patient preferences. The AUA/SUFU guideline recommends counseling patients about the side effects of oral OAB medicines and selecting treatment through shared decision-making.

For providers, the availability of different pharmacological mechanisms can reduce reliance on a single class when adverse effects, contraindications, or inadequate symptom control become concerns.

Relevance to urology and BPH management

The expanded indication gives Gemtesa a more direct role in the overlap between OAB and BPH. This is important because urinary urgency, frequency, nocturia, and urge incontinence may persist even when men are receiving medication directed at prostate-related symptoms.

The COURAGE data provide evidence for adding a β3 agonist to the treatment pathway in this population without showing a meaningful increase in urinary retention compared with placebo in the studied trial.

This can influence prescribing workflows in urology, where clinicians already manage both prostate-related obstruction and storage symptoms.

Potential implications for treatment persistence

Treatment persistence is a recurring challenge in OAB because symptoms are chronic and medication adverse effects can influence whether patients continue therapy. A drug with a differentiated tolerability profile can therefore compete not only on symptom improvement but also on the likelihood that patients remain on treatment.

This is especially relevant for older populations, who often have multiple chronic conditions and take several medications. Gemtesa’s lack of a hypertension warning in the U.S. label and its relatively limited drug-interaction profile have been highlighted by Sumitomo Pharma as commercial differentiators. At the same time, clinicians still need to consider urinary retention, hypersensitivity reactions, and the interaction with digoxin described in the prescribing information.

Market and Business Implications

A differentiated position in a mature therapeutic category

The commercial opportunity for Gemtesa does not depend on creating an entirely new OAB market. Instead, the strategy is based on capturing share within an established treatment category through differentiated pharmacology, evidence, and patient segmentation.

That distinction is important for market researchers. OAB is a mature pharmaceutical market with multiple generic and branded treatment options. Consequently, prescription growth for Gemtesa depends on switching, new treatment starts, combination strategies, and deeper penetration into populations where its clinical characteristics may be attractive.

The male OAB/BPH indication is particularly relevant because it creates a clearly defined expansion pathway. Sumitomo Pharma has explicitly stated that increasing prescriptions among men is part of its commercialization strategy.

Competition with mirabegron

Mirabegron is the most direct branded pharmacological comparator because it also acts on β3-adrenergic receptors. Gemtesa therefore competes against another mechanism-based alternative rather than simply challenging antimuscarinic medicines.

The distinction between the products includes labeling, pharmacokinetics, drug interactions, safety considerations, pricing, payer coverage, and physician familiarity. The AUA/SUFU guideline specifically notes that mirabegron and vibegron have different warnings related to hypertension, with vibegron not carrying the same severe uncontrolled-hypertension warning present in the mirabegron label.

For commercial strategy, this means that Gemtesa’s competitive differentiation can be communicated through several dimensions rather than relying solely on comparative symptom reduction.

Pricing and reimbursement remain important.

Gemtesa’s sales trajectory also demonstrates the importance of payer policy. Sumitomo Pharma reported that changes in Medicare Part D coverage affected prescription volume in 2025, while pricing effects and rebate changes contributed positively to reported sales.

This is a useful reminder that prescription volume and pharmaceutical revenue do not always move in parallel. For branded medicines, formulary placement, rebates, patient out-of-pocket costs, Medicare policy, and gross-to-net adjustments can materially influence commercial performance.

From a market-access perspective, Gemtesa therefore competes on both clinical value and economic positioning. The company’s stated strategy of balancing price and volume illustrates the challenge of maintaining access while protecting product economics.

Opportunities beyond the original OAB population

The BPH-associated OAB indication is the clearest current expansion opportunity. Additional real-world evidence, subgroup analyses, and longer-term data can potentially strengthen confidence among clinicians treating complex patients.

Research in combination and treatment-switching strategies is also relevant. For example, the ADVISR trial protocol is evaluating whether adding vibegron to an antimuscarinic or switching from an antimuscarinic to vibegron is more useful in patients with inadequate initial response. This remains an investigational research question rather than an established Gemtesa indication.

Such research could become commercially meaningful if it produces evidence supporting specific treatment pathways, but current results should not be interpreted beyond the populations and designs actually studied.

Key Companies and Industry Participants

Sumitomo Pharma

Sumitomo Pharma is the principal company behind Gemtesa’s current U.S. commercialization. The company has made Gemtesa one of its core U.S. products and is using the expanded BPH-associated OAB indication to deepen penetration among male patients. Its 2026 Boost 2028 strategy also places Gemtesa alongside ORGOVYX as a major contributor to future sales.

Urovant Sciences

Urovant was the sponsor responsible for the U.S. development program leading to Gemtesa’s 2020 approval. FDA review documents show that the vibegron development program had originally been initiated by Merck, with U.S. responsibilities transferred to Urovant in 2017.

The historical development pathway illustrates how ownership and commercialization structures can change during the life cycle of a pharmaceutical asset.

Kyorin Pharmaceutical and Kissei Pharmaceutical

Vibegron has a separate history in Japan, where Kyorin and Kissei Pharmaceutical co-developed and co-marketed the product under the Beova brand. Kyorin reports that Beova was launched in 2018 and generated ¥22.1 billion in sales in fiscal 2024.

The Japanese business demonstrates that the commercial trajectory of vibegron is not limited to the U.S. Gemtesa market. It also provides a useful reference for understanding how β3 agonists have developed in Japan’s OAB treatment market.

Other industry participants

Astellas is relevant because mirabegron, marketed as Myrbetri in the United States and under other brand names in international markets, represents the other major β3-agonist competitor. Generic manufacturers also remain important because antimuscarinic medicines and other established OAB therapies can be substantially more cost-competitive.

Urologists, primary care physicians, pharmacists, payers, and healthcare systems are equally important stakeholders because prescribing decisions depend on clinical evidence, reimbursement, patient characteristics, and medication affordability.

Challenges and Limitations

Gemtesa’s market position remains subject to several limitations.

First, OAB is a competitive category with numerous established medicines. Generic antimuscarinics can create substantial price pressure, while mirabegron gives prescribers a familiar β3-agonist alternative. Demonstrating a differentiated clinical value proposition therefore remains important.

Second, clinical benefits need to be considered alongside safety monitoring. The U.S. label warns about urinary retention, particularly in patients with bladder outlet obstruction or those taking muscarinic antagonists. Angioedema, including potentially serious swelling involving the airway, has also been reported. Gemtesa can increase digoxin exposure, requiring monitoring when the medicines are used together.

Third, clinical trial populations do not represent every patient encountered in routine practice. COURAGE provides useful evidence for men with OAB and pharmacologically treated BPH, but its findings should not automatically be generalized to every form of bladder outlet obstruction or every patient with lower urinary tract symptoms.

Fourth, reimbursement can alter commercial performance independently of clinical demand. Sumitomo Pharma’s own disclosures concerning Medicare Part D demonstrate how coverage decisions can influence prescription volume, pricing, and net sales.

Finally, international commercialization is fragmented. Vibegron is marketed under different names and through different companies in different markets, including Gemtesa in the United States and Obgemsa in the European Union. The EMA authorized Obgemsa for adults with OAB, illustrating that regulatory positioning and commercial branding differ by geography.

Future Outlook

Gemtesa’s near-term outlook is likely to remain closely connected to the commercial execution of its expanded U.S. indication. The BPH-associated OAB population provides Sumitomo Pharma with a defined opportunity to increase prescribing among men, while longer-term COURAGE evidence can support discussions around durability and bladder-function safety.

The broader OAB market is also likely to remain influenced by the balance between efficacy and tolerability. β3 agonists have an important role in that discussion because they offer an alternative mechanism to antimuscarinic medicines. Future treatment selection may increasingly depend on patient age, comorbidities, cognitive-risk considerations, cardiovascular factors, concurrent medications, and prior treatment response rather than on symptom efficacy alone.

Further real-world evidence could also be commercially valuable. Data from routine urology practice can help clarify persistence, switching patterns, treatment sequencing, adherence, healthcare utilization, and outcomes in populations that are less represented in controlled trials.

Combination and sequencing research is another area worth monitoring. Studies examining whether vibegron should be added after an inadequate antimuscarinic response or used as a replacement therapy could provide additional information about how β3 agonists fit into treatment algorithms. These remain research questions rather than established indications for Gemtesa.

From a company perspective, Sumitomo Pharma’s decision to place Gemtesa at the center of its U.S. growth strategy means continued investment in physician education, market access, evidence generation, and patient awareness is likely to remain important. The company’s Boost 2028 strategy indicates that Gemtesa is being treated as a core commercial franchise rather than a peripheral product.

Conclusion

Gemtesa has developed into an important branded therapy within the U.S. OAB market, supported by its β3-adrenergic mechanism, once-daily administration, established clinical evidence, and an expanded indication for men with OAB who are receiving pharmacological treatment for BPH.

The 2024 U.S. label expansion is particularly significant because it gives Sumitomo Pharma a larger and more clearly defined population in which to compete. Results from the COURAGE program strengthen the evidence supporting this use, including data on symptom improvement, patient-reported outcomes, and bladder-function safety.

Commercially, Gemtesa illustrates how differentiation in a mature pharmaceutical category can come from a combination of mechanism, labeling, evidence generation, and market-access strategy. Its reported U.S. sales growth and inclusion in Sumitomo Pharma’s long-term growth strategy reinforce its importance to the company.

At the same time, Gemtesa faces a competitive environment shaped by generic antimuscarinics, mirabegron, reimbursement pressures, and the need to demonstrate value across diverse patient populations. Its future market performance will therefore depend not only on prescription growth but also on how effectively clinical evidence translates into sustained adoption, payer coverage, and treatment persistence.

For the healthcare market, Gemtesa represents a useful example of the continuing shift toward differentiated pharmacological options for chronic urological conditions. Its progress will be closely tied to evidence from real-world practice, treatment sequencing research, payer decisions, and the ability of β3 agonists to capture a larger role in OAB management.

Source References

• U.S. Food and Drug Administration (FDA), GEMTESA (vibegron) Approval Package, December 2020.
• U.S. Food and Drug Administration (FDA), GEMTESA Prescribing Information, revised February 2025.
• DailyMed, GEMTESA (vibegron) Drug Label Information, National Library of Medicine.
• American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder, 2024.
• Staskin D, et al., International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR, Journal of Urology.
• Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR), Journal of Urology.
• Peters KM, et al., Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial, Urology, 2025.
• Rovner ES, et al., Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial, Neurourology and Urodynamics, 2026.
• European Medicines Agency (EMA), Obgemsa (vibegron) European Public Assessment Report.
• European Medicines Agency (EMA), Obgemsa: Overview.
• Sumitomo Pharma, Integrated Report 2025.
• Sumitomo Pharma, FY2025 Financial Results and Gemtesa Business Updates, 2025.
• Sumitomo Pharma, Boost 2028 Corporate Growth Strategy, 2026.
• Kyorin Pharmaceutical, Annual Report 2025.
• PubMed-indexed literature on vibegron efficacy, long-term safety, β3-adrenergic agonists, and OAB treatment.